NATIONAL
CANCER
INSTITUTE

NCI Cancer Bulletin
A Trusted Source for Cancer Research News
November 6, 2007 • Volume 4 / Number 29 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe


Bulletin Home

Featured Article
Drug Improves Induction Chemo for Head & Neck Cancers

Director's Update
HIV/AIDS Research at NCI: A Record of Sustained Excellence

Cancer Research Highlights
Vitamin D May Affect Colorectal Cancer Mortality

Brain Cancer Trial Finds Longer Survival with Temozolomide Regimen

Patient Navigators Tailor Interventions in Minority, Low-Income Populations

"Boost" Radiation Offers Benefits for Women with Early-Stage Breast Cancer

Funding Opportunities

Special Report
New Guidelines Favor Chemo as Adjuvant Therapy for NSCLC

Featured Clinical Trial
Targeted Combinations for Metastatic Kidney Cancer

Portrait of Former NCI Director Unveiled

Notes
Director Named for Advocacy Relations

Lowy, Schiffman Receive ACS Medals of Honor

Niederhuber, Udey Named 2007 AAAS Fellows

NCI Hosts Public Forums on Biospecimen Resources

Teleconference Focuses on NCI-Frederick

NCI 70th Anniversary: If Memory Serves...

Community Update
Treating the Whole Person

Bulletin Archive

About the Bulletin

Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
View/Print PDF
Featured Article

Drug Improves Induction Chemo for Head and Neck Cancers

For patients with advanced head and neck cancers who receive an initial treatment of chemotherapy prior to other therapies, three drugs appear to be better than two. Patients who received docetaxel (Taxotere) in addition to the standard combination of cisplatin and fluorouracil had better outcomes than those taking cisplatin and fluorouracil alone, according to findings in the October 25 New England Journal of Medicine.

The results are from two randomized clinical trials that evaluated the addition of docetaxel to standard chemotherapy for patients receiving induction (or neoadjuvant) treatment. This treatment is given before radiation-based therapy, as was the case in the two reported clinical trials, and/or surgery.  Read more  



Director's Update

HIV/AIDS Research at NCI: A Record of Sustained Excellence

Drs. Mitch Mitsuya, Samuel Broder, and Robert Yarchoan were honored at last week's symposium for their work on HIV/AIDS. Also recognized was Dr. Robert Gallo (not pictured).

Drs. Mitch Mitsuya, Samuel Broder, and Robert Yarchoan were honored at last week's symposium for their work on HIV/AIDS. Also recognized was Dr. Robert Gallo (not pictured).

The human immunodeficiency virus (HIV) and the disease it causes, Acquired Immune Deficiency Syndrome (AIDS), announced itself in the United States in 1981, in the form of a small, sudden uptick in reports of a rare cancer, Kaposi sarcoma (KS), and a rare form of pneumonia among young gay men in New York and San Francisco. That same year, in the NIH Clinical Center, NCI physicians treated the first patient with this deadly, yet-to-be-named disease.

NCI's history will forever be intertwined with that of HIV and AIDS. NCI scientists were at the forefront of the effort to identify HIV as the cause of AIDS, characterize how it hijacked cellular machinery, and, in turn, develop the first treatments for it.  Read more  


The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI). NCI, which was established in 1937, leads the national effort to eliminate the suffering and death due to cancer. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.

For more information on cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.

NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.

Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov